IndiaCatalog.com
Login Signup
IndiaCatalog.com
Home Web Directory Classifieds Yellow Pages Global Directory City Guide News Photo Galleries
Login
Signup
  • Home
  • Global Web Directory
  • Drugs
Biotechnology
Diagnostic Substances
Drug Delivery
Drug Manufacturers - Major
Drug Manufacturers - Other
Drug Related Products
Drugs - Generic

Nutrition 21, Inc.

Nutrition 21, Inc.

Nutrition 21, Inc. company was founded in 1983 and is headquartered in Purchase, New York. Nutrition 21, Inc., a nutritional bioscience company, develops, markets, and distributes proprietary and clinically substantiated nutritional supplements in the United States. The company sells Chromax branded chromium picolinate to vitamin and supplement and food manufacturers and marketers, as well as directly to retailers for use in human and animal nutrition products. It also develops and commercializes Diabetes Essentials, a proprietary, non-prescription, insulin sensitizer for people with type 2 diabetes. In addition, the company offers a portfolio of health and wellness products under the Iceland Health Maximum Strength Omega-3, Iceland Health Joint Relief, Iceland Health Advanced Memory Formula, Chromax chromium picolinate, Prescriptix Supplements, and Diabetes Essentials names. In addition, Nutrition 21, Inc. grants patent licenses to its ingredients to manufacturers and marketers of vitamin and mineral supplements.

Evotec AG

Evotec AG

Evotec AG (Evotec) is a drug discovery and development company focused on small molecule therapeutics. Evotec is developing treatments for diseases in the areas of neuroscience, pain, and inflammation. Evotec’s portfolio comprises five clinical drug candidates: EVT 101, a subtype selective NMDA receptor antagonist with potential for the treatment of Alzheimer’s disease, pain and depression, EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 302, a MAO-B inhibitor in development for smoking cessation, a P2X7 antagonist for the treatment of inflammatory diseases, and a small molecule vanilloid receptor (VR1) antagonist for the treatment of pain in partnership with Pfizer. Evotec’s late stage preclinical research programs focus on EVT 103, a back-up compound to EVT 101, H3 antagonists for the treatment of cognitive disorders and/or sleep, as well as antagonists for the purinergic receptor P2X3 for the treatment of pain.

Adolor Corporation

Adolor Corporation

Adolor Corporation was founded in 1993 and is headquartered in Exton, Pennsylvania. Adolor Corporation is a biopharmaceutical company. The Company has specialized in the discovery and development of prescription pain management products. It has a number of product candidates in various stages of development, ranging from preclinical studies to pivotal clinical trials. On May 20, 2008, the United States Food and Drug Administration (FDA) approved the Company’s first product, ENTEREG (alvimopan), for the management of postoperative ileus following bowel resection surgery (POI). ENTEREG is specifically indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. The Company in collaboration with Glaxo Group Limited (Glaxo), launched ENTEREG in the United States in mid-2008.

ARIAD Pharmaceuticals, Inc.

ARIAD Pharmaceuticals, Inc.

ARIAD Pharmaceuticals, Inc. company was founded in 1991 and is based in Cambridge, Massachusetts. ARIAD Pharmaceuticals, Inc. (ARIAD) is a biopharmaceutical company engaged in the discovery and development of medicines to treat cancers by regulating cell signaling with small molecules. The Company’s lead cancer product candidate, deforolimus, is an internally discovered, potent inhibitor of the protein mTOR, a master switch in cancer cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism and angiogenesis. Its second product candidate, AP24534, is a multi-targeted kinase inhibitor that has potential applications in cancer and is wholly owned by the Company. The company also focused drug discovery program centered on small-molecule therapies, molecularly targeted to cell-signaling pathways implicated in cancer. It also developed a portfolio of cell-signaling regulation technologies, its ARGENT technology, to control intracellular processes with small molecules.

CytoGenix, Inc.

CytoGenix, Inc.

CytoGenix, Inc. company was founded in 1995 and is based in Houston, Texas. CytoGenix, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of its proprietary technologies for identifying and silencing disease causing genes; and expressing proteins for applications, such as vaccines and isolating novel nucleic acid-based anti-microbial compounds. The company’s technologies include gene silencing techniques (ssDNA) applicable to genes from pathogenic organisms or selected genes from a patient to prevent the expression of harmful proteins; a novel, cell free process to produce large quantities of DNA (synDNA) for use in its own products and for sale to other biopharmaceutical or life science companies; and a methodology to isolate and characterize novel DNA-based drugs (Oligogenix) to which harmful bacteria have not developed resistance. Its products under development include SIMPLIVIR, an anti-herpes topical compound; Oligogenix technique based compounds against methicillin and vancomycin resistant staphylococcus aureus; and DNA vaccines for use in humans, poultry, aquaculture, and cattle. The company in collaboration with the United States Department of Agriculture, engages in a project to develop a synDNA based vaccine against brucellosis, a zoonotic disease which is easily transmitted from animals to humans.

Biosite Incorporated

Biosite Incorporated

Biosite Incorporated company's diagnostic products include its Triage Drugs of Abuse Panel and Triage TOX Drug Screen which are used in hospital settings to test for commonly abused drugs. Its other diagnostic products include tests to detect intestinal parasites, diagnose congestive heart failure, and measure the biomarkers associated with stroke. The Biosite Discovery program is a collaborative research effort to identify protein markers for a variety of ailments. Medical diagnostics firm Inverness Medical Innovations acquired Biosite in 2007.

Peplin, Inc.

Peplin, Inc.

Peplin, Inc. company is developing drugs aimed at treating potentially cancerous skin conditions. Its lead drug candidate, a topical gel, is intended to serve as a less-costly alternative to surgical treatments for a common pre-cancerous skin condition known as actinic keratosis (AK). Derived from a plant known as petty spurge or radium weed, the product will be used to treat AK (characterized by rough patches of skin resulting from excessive exposure to sunlight) before it develops into skin cancer. Peplin was acquired by pharmaceutical giant LEO Pharma in late 2009 for $285 million.

Alimera Sciences, Inc.

Alimera Sciences, Inc.

Alimera Sciences' tunnel vision is a real asset. The biopharmaceutical company specializes in prescription ophthalmic pharmaceuticals, particularly those aimed at treating ocular diseases affecting the retina. Alimera's most advanced product candidate, Iluvien, is an insert about the size of a grain of rice that slowly releases a drug to the back of the eye used in the treatment of diabetic macular edema (DME); DME, a retinal disease affecting diabetics, can lead to severe vision loss and blindness. Iluvien is effective for up to 36 months and may also have the potential to affect other ophthalmic diseases, such as retinal vein occlusion (RVO). Alimera Sciences is looking to go public through an $80 million IPO.

IS Pharma plc

IS Pharma plc

IS Pharma, formerly known as Maelor, is a UK-based drug and medical device company focused on products for the hospital market; it sells directly in the UK and uses distributors elsewhere. Among its products are Volpex, Haemopressin, and ISOplex, all critical care products used in surgery; Mysoline, an oral treatment for epilepsy; and Cryogesic and Aloxi, two cancer drugs. Maelor outlicenses some products outside its core focus areas to other firms, including its OptiFlo catheter, which is distributed by C.R. Bard. Previously limited primarily to the UK market, the firm bought Swiss drug firm Specialty European Pharma International in 2008, giving it a wider presence in Europe and in North America.

Medical Nutrition USA, Inc.

Medical Nutrition USA, Inc.

Medical Nutrition USA, Inc. engages in the development and distribution of nutritional and health products in the United States. Its products primarily include the Pro-Stat line of enzyme-hydrolyzed liquid protein for the treatment of unintended weight loss, protein energy malnutrition, and pressure ulcers; UTI-Stat, a urinary tract cleansing complex used to reduce the incidence of urinary tract infection and promote urinary tract health; and Fiber-Stat, a liquid soluble fiber with FOS used to maintain bowel regularity and probiotic intestinal health. Medical Nutrition company's customers include long-term care facilities, hospitals, dialysis clinics, physicians, dispensing medical clinics, nursing homes, and network marketing companies. Medical Nutrition USA sells its branded products directly to distributors, who resell the products to end users, as well as sells through health food stores under private label or licensing agreements. Medical Nutrition USA, Inc. is based in Englewood, New Jersey.

Post a FREE Classified Advertisement

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.

Most Read News

IndiaCatalog News
India's first private orbital rocket Vikram-1 lifts off from Sriharikota
IndiaCatalog News
Plea before SC seeks CBI probe into 'KG Basin gas extraction' by Reliance
IndiaCatalog News
Sonam Wangchuk's wife moves Delhi HC against order on his treatment
IndiaCatalog News
CJP's 'Chalo Sansad' March in Delhi today: Here's all you need to know
IndiaCatalog News
PNB Q1FY27 result: Net profit jumps over threefold to ₹5,253 crore

CORPORATE NEWS

Oracle India Private Limited.
Oracle India Private Limited.
Wipro Technologies (Wipro Ltd)
Wipro Technologies (Wipro Ltd)
Hyundai Motor India Ltd.
Hyundai Motor India Ltd.
Bombay Stock Exchange - BSE
Bombay Stock Exchange - BSE
Essar Oil Ltd.
Essar Oil Ltd.
Defence Research and Development Organization (DRDO)
Defence Research and Development Organization (DRDO)
Securities and Exchange Board of India ( SEBI )
Securities and Exchange Board of India ( SEBI )
Essar Power Ltd.
Essar Power Ltd.
IndiaCatalog.com

IndiaCatalog.com is a website brought to you by Portland Technologies to provide directory of Indian websites, News, City Guides and profiles of Indian Businesses. Portland Technologies also provides IT solutions for Small and Medium Businesses in India.


Products

India Web Directory

Global Web Directory

Yellow Pages

Photo Galleries

FREE India Classifieds


Useful links

About us

Advertise

Link to us

Submit a Site

Business Reviews


Contact

Plot #37, Ramnagar Gundu, Hyderabad - 500 044

service@indiacatalog.com

+91-40-23756949


© Copyright: IndiaCatalog.com